BIM bioMerieux S.A.

Mérieux NutriSciences and bioMérieux Issue the Results of a Food Safety Survey for the World Food Safety Day

For this inaugural World Food Safety Day, Mérieux NutriSciences and bioMérieux conducted an international consumer survey1 to better understand consumer perception and behaviors towards food safety in four countries: the United States, China, France and India. Even if food safety seems to be a growing concern for these four countries, the results highlight different perceptions and expectations from one country to another.

When it comes to food safety, 96% of respondents in China declared that they are confident in the food they consume, 93% in India and 90% in the United States. In France however, only 65% declared to be confident in the food they consume. 52% of French people interviewed claim they feel not enough informed about the safety of the food they consume. Indians (86%), Americans (80%) and Chinese (77%) for their part feel well informed about this topic.

In terms of behavior, the best before date is the most important criteria in India (68%) and in the United States (61%). The best before date is considered a guarantee only for 33% of the French, focusing mainly on the origin, the traceability (71%), the composition of the product (63%), the existence of quality labels (41%).

The brand of the product is not considered as an important guarantee of food safety in France (11%), whilst coming in fourth place in China (42%), third place in India (43%) and fifth place in the United States. Another major difference between these countries is that the origin and the traceability of the product, is the number one criteria in France, number three in China whereas it is not even listed in the top 3 in India and in the United States.

As a leader in microbiological food control, we are committed to protecting the health of consumers and the survey we have co-funded reveals that the criteria all four nations agree on as being a concern, is the presence of bacteria in food, rated in the top 3 by Americans, Chinese, Indians and French people. This illustrates the importance of the microbiological quality of food and beverage for consumers from these 4 countries,” said Nicolas Cartier, Executive Vice President, Industrial Microbiology Unit at bioMérieux.

Among the six criteria used in the survey (presence of chemicals in food, food fraud, presence of bacteria, use of new technologies, presence of viruses, traces of allergens), Americans (64%) are, on average, less worried than French (78%), Indians (81%) and particularly Chinese (89%).

When looking at the future, guaranteeing that a product does not present any bacteriological or poisoning risks remains instrumental. It will also become important to ensure that the product is free of preservatives, not carcinogenic, organic and with an acceptable carbon footprint,” said Philippe Sans, President & CEO of Mérieux NutriSciences.

This implies major behavioral changes in many countries. Regarding the packaging, French (92%), Chinese (72%), Indians (87%) and Americans (83%) are predominantly willing to accept the evolutions: less individual packaging, less plastic and more returnable glass. However, a minority of French (45%) and Americans (49%) would accept to pay more for healthier and safer food. Indians (72%) and Chinese (73%) would gladly consent.

For this first World Food Safety Day, this survey draws attention to the fact that Food Safety is crucial across geographies, and is everyone’s concern.

_______________
1   ODOXA survey conducted between April 30 and May 14, 2019 among a representative sample of the French population aged 18 and over, of 1000 people, a representative sample of the Chinese population aged 18 and over, of 1002 persons, a representative sample of the United States population aged 18 and over, 1005 persons and a representative sample of the Indian population aged 18 and over, of 1005 persons.
 

ABOUT MÉRIEUX NUTRISCIENCES

A world player in food safety and quality for more than 50 years, Mérieux NutriSciences is present in 23 countries through more than 100 laboratories.

As part of Institut Mérieux, Mérieux NutriSciences offers analytical and product development solutions to prevent health risks related to food and more generally to the use of everyday consumer products. The company also offers digital solutions as part of its dedicated business unit.

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 43 countries and serves more than 160 countries with the support of a large network of distributors. In 2018, revenues reached €2.4 billion, with over 90% of international sales.

bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. Its diagnostic solutions are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market.

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP

Corporate website:

EN
07/06/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports by bioMerieux S.A.

latest_report

Martial Descoutures ...
  • Thibaut Voglimacci

Prudents sur le redressement des marges - VENTE - OC 122€

Nous initions la couverture avec une recommandation à VENTE et un objectif de 122€ dérivant d’une moyenne d’un DCF (122€) et de multiples de comparables (123€). Nous considérons que le marché a surréagi aux bons résultats semestriels occultant différents éléments (consolidation, baisse des remboursements, concurrence) qui impacteront la croissance des ventes et la dynamique de progression de la rentabilité. La valorisation actuelle est justifiée dans un « scénario bull » (CA TMVA 15-19e: +9,8%, marge EBITA 2019: 17,8%) mais celui-ci nous paraît difficilement réalisable. Nous sommes néanmoins c...

Martial Descoutures ...
  • Thibaut Voglimacci

Une croissance solide mais une valorisation tendue - VENTE - OC 123€ (vs 149€)

La publication des ventes T3 est ressortie légèrement supérieure à nos estimations. Comme attendu, la guidance de CA 2016 sera certainement dépassée. Malgré un relèvement de notre estimation de croissance 2016 et de notre objectif à 123€ vs 122€, nous continuons de penser que la valorisation actuelle est difficilement justifiable dans une perspective MT. Selon nous, elle n’intègre pas différents éléments nuisant à la croissance des ventes et au redressement rapide des marges. VENTE réitérée.

Michael Waterhouse

BioMerieux Should Continue to Post Strong Growth and Margin Expansion in 2017

We’re leaving our fair value estimate for narrow-moat BioMerieux unchanged, as the firm’s 7.8% constant-currency growth in the fourth quarter combined with 14.2% adjusted operating margin for the year nearly matched our expectations. We don’t plan any major changes to our forecast, as management’s outlook for 8% to 9% constant-currency growth and adjusted operating income of EUR 300 million to EUR 315 million also meets our expectations when accounting for slight negative currency effects. Even ...

Martial Descoutures ...
  • Thibaut Voglimacci

Guidance prudente, valorisation tendue - VENTE - OC 129€ (vs 126€)

La publication des résultats 2016 s’est révélée globalement en ligne mais pénalisée par une guidance d’EBITA décevante. En 2017, la croissance lfl du CA est prévue entre +8/+9% et le niveau d’EBITA devrait s’établir dans la fourchette de 300/315m€ (impact FX att de -30m€). Nous restons prudents sur la croissance organique du groupe (+7,8% att par IS) face aux perspectives de densification de la concurrence et abaissons notre estimation d’EBITA 2017e de -3,4% intégrant des frais R&D/SG&A en hausse malgré des COGS en baisse. Opinion VENTE réitérée avec un objectif relevé à 129€ (vs 126€ préc.).

Martial Descoutures ...
  • Thibaut Voglimacci

Un record au T1 17, prudence sur la rentabilité - VENTE - OC 143€ (vs 129€)

La publication des ventes au T1 17 (croissance lfl de +13,7%) atteint un record. Le groupe prend ainsi une avance confortable sur sa guidance annuelle (+8%/+9%) qui devrait être relevée au S1 17. Sur 2017, les forces de résistances (Virtuo, nouveaux tests FilmArray RP, indications PCT) dernièrement mises en place devraient protéger la croissance de la concurrence et stimuler les parts de marché. Nous relevons nos estimations de CA 17e/18e/19e de +2,2%/+3,8%/+4,7%et ajustons notre OC à 143€ vs 129€ préc. Néanmoins, nous conservons notre recommandation à l’approche de la régulation PAMA en 2018 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch